This Event has Passed
Monday, November 14, 2016 - 8:30 AM
to Tuesday, November 15, 2016 - 5:30 PM
8:30 AM - 5:30 PM See all dates and Times
https://go.evvnt.com/61745-0
Broadening horizons on the growing global threat of Antimicrobial resistance (AMR) for almost two decades at the sell-out Superbugs and Superdrugs conference in Europe, SMi is thrilled to announce the expansion of its antimicrobial portfolio of events across the Atlantic with the release of Superbugs and Superdrugs USA.
This year's show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.
With huge interest from leaders in the field including pending confirmations from PAHO/WHO, Astra Zeneca and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs and Superdrugs event to date.
The programme will hone in on key topics such as public private partnerships, collaboration, RandD, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!
Featured speakers include:
Dr Christopher Houchens, Branch Chief, Antibacterial's Program, BARDA
Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section , NIH
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research and Development LLC
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
Dr Alita Miller, Director of Biology, Entasis Therapeutics
William J Weiss, Director, Pre-Clinical Services, UNT Health Science Center
Dr Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
Dr David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
Register early to take advantage of early bird savings at www.superbugs-usa.com or contact Teri Arri on email: [email protected], tel: +44 (0)20 7827 6162
This year's show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.
With huge interest from leaders in the field including pending confirmations from PAHO/WHO, Astra Zeneca and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs and Superdrugs event to date.
The programme will hone in on key topics such as public private partnerships, collaboration, RandD, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!
Featured speakers include:
Dr Christopher Houchens, Branch Chief, Antibacterial's Program, BARDA
Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section , NIH
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research and Development LLC
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
Dr Alita Miller, Director of Biology, Entasis Therapeutics
William J Weiss, Director, Pre-Clinical Services, UNT Health Science Center
Dr Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
Dr David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
Register early to take advantage of early bird savings at www.superbugs-usa.com or contact Teri Arri on email: [email protected], tel: +44 (0)20 7827 6162
